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An Easily Forgiven “Latecomer”We are thankful to De Rosa and colleagues for their additional
analysis of, and insight into the topic covered in our report (1).
Although we were unable to directly replicate their ﬁndings, their
ﬁndings are interesting and hypothesis generating. It is conceivable
that aspiration thrombectomy will have a U-shaped relationship with
ischemic time when more trials are included. With longer ischemic
times, the thrombus becomes more organized and is subsequently
harder to retrieve with manual aspiration catheters. This hypothesis
should be actively investigated in future studies on this topic.*Dharam J. Kumbhani, MD, SM
Anthony A. Bavry, MD, MPH
Milind Y. Desai, MD
Sripal Bangalore, MD, MHA
Deepak L. Bhatt, MD, MPH
*Division of Cardiology
University of Texas Southwestern Medical Center
5323 Harry Hines Boulevard
Dallas, Texas 75390-9047
E-mail: dharam@post.harvard.edu
http://dx.doi.org/10.1016/j.jacc.2014.01.028REFERENCE
1. Kumbhani DJ, Bavry AA, Desai MY, Bangalore S, Bhatt DL. Role
of aspiration and mechanical thrombectomy in patients with acute
myocardial infarction undergoing primary angioplasty: an updated meta-
analysis of randomized trials. J Am Coll Cardiol 2013;62:1409–18.Cardiovascular Prevention
in Diabetes Mellitus
No Magic Remedies
Cardiovascular (CV) prevention has long been a target of clinical trials
in diabetes mellitus (DM). Several of those trials, however, have been
unsuccessful. In an effort to address this issue, the recently published
PONTIAC(NT-proBNPGuidedPrimaryPrevention ofCVEvents
in Diabetic Patients) trial used natriuretic peptides (NPs) to select
patients who had a relatively greater need for CV prevention and
hence were probably more prone to improvement (1). This study was
successful, but there were some questions that arise from this and
previous trials on CV prevention in DM.
First, was the poor patient selection the main reason why the
previous trials failed? The interventions used by some of the pre-
vious trials also may have not been successful. For example, in the
ROADMAP (Randomized Olmesartan and Diabetes Micro-
albuminuria Prevention) trial, a high dose of an effective angiotensin
receptor inhibitor (20 mg olmesartan) was used to prevent micro-
albuminuria in patients with DM who did not have hypertension,
which resulted in high rates of hypotension and other complications
and thus treatment failure (2,3). In the PONTIAC trial, a small but
signiﬁcant decline in estimated glomerular ﬁltration rate observed in
the intensiﬁed treatment group may be of some concern.
Second, what is the underlying pathophysiology for a mild in-
crease in NP levels in symptomatic patients with DM but without
known cardiac disease? There are several reasons for false-positive
or negative NP results, particularly in a population such as those
with DM, characterized by increased rates of comorbidities such as
renal dysfunction or obesity. In other words, what is the patho-
genetic process that we treat in those patients, and is the neuro-
hormonal blockage a suitable treatment for this process? In the
PONTIAC trial, there was no signiﬁcant reduction in NP levels in
the intensiﬁed treatment group during the study period, and thus
the reason for elevated levels of NP at baseline was probably not
addressed by the applied intervention.
Third, how should we titrate and monitor neurohormonal
blockade therapy in patients without a clear evidence-based indica-
tion for such a therapy, such as arterial hypertension or heart failure?
In the PONTIAC trial, treatment titration could not have been
guided or followed by NPs, because there was no signiﬁcant differ-
ence in NP levels between the 2 study groups at the end of the study.
Finally, could the positive results of the PONTIAC trial be
explained solely by the increased use of health care resources in
the intensiﬁed treatment group? Those patients were seen regu-
larly not only by diabetologists but also by cardiologists in the
cardiac outpatient clinics where they were receiving individu-
alized treatment, and that may be a sufﬁcient reason for a better
outcome. In other words, the success of the PONTIAC trial may
not lie on the use of NPs for patient selection but instead on the
